Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Migalastat in Fabry Disease with Severe Renal Impairment or ESRD
NCT04020055Phase 3Active, not recruiting
- Sponsor
- Amicus Therapeutics
- Start
- Oct 2022
- Primary completion
- Dec 2026
- Modality
- Classical Binding Small Molecules
- Countries
- 6
01
Overview
A Phase 3 trial of migalastat in Fabry disease (FD), sponsored by Amicus Therapeutics. Started Oct 2022; status: active, not recruiting.
02
Drugs
migalastat
03
Conditions
Fabry disease (FD)
Beyond the preview
Go deeper on NCT04020055.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04020055.